



FOR RELEASE
January 12, 2022

MBF Therapeutics Announces Issuance of a U.S. Patent for Its T-Max™ DNA Vaccine Platform

Contacts:

Thomas Tillett
CEO, MBF Therapeutics
ttillett@mbftherapeutics.com
www.mbftherapeutics.com

Len Smith
Principal Counsel, Transformative Legal
Email: info@transformativelegal.com
www.transformativelegal.com

Ambler, Penn., (NEWSWIRE) – MBF Therapeutics, Inc., an immunotherapeutics company using its innovative, proprietary T-Max™ DNA vaccine platform to deliver commercial vaccines that provide safe, durable, polyvalent protection against endemic, emerging and re-emerging viral diseases of global concern, today announced that it has been awarded US Patent 11,130,787, a foundational patent that provides new compositions and methods using DNA and RNA to induce immune responses to treat or prevent viral diseases and cancer in humans, livestock and companion animals.

MBF Therapeutics is taking a fundamentally different approach to vaccine design using its patented T-Max™ technology platform to develop protective T cell vaccines that prevent disease by rapidly clearing pathogens and infected cells at the earliest stage of infection to protect and prevent individual-to-individual transmission at the population level. Vaccines designed to elicit antibody immunity provide highly effective protection to individuals by reducing disease severity, but they do not prevent the transmission among individuals that sustains pandemic conditions and leads to the continuous evolution of infectious variants such as SARS CoV2 Delta and Omicron.

The T-Max™ platform provides for needle-free, storage stable vaccines that can be manufactured and distributed anywhere, to address the need for universal vaccine access that stops transmission that is essential to global pandemic control.

Tom Tillett, CEO of MBFT commented, “The demand for a new approach to vaccine development has never been more evident than it is today, as demonstrated by the continued global negative impact of infectious disease on man and animals. Coronavirus (COVID-19, SARS, MERS) and influenza viruses are great examples of persistent human pandemic threats. African Swine Fever and Porcine Reproductive and Respiratory Syndrome in pigs are devastating diseases and serious threats to the world’s food supply. MBFT technology promises a more effective, polyvalent, longer-lasting, readily adaptable and straightforward to manufacture vaccine platform to block infection and prevent transmission: a different and disruptive approach to infectious disease management. We are particularly excited by the speed with



which this application was reviewed and allowed, and that broad claims strongly support our overall platform approach.” I want to thank our CSO, Dr. Lorraine Keller and our patent attorney Len Smith of Transformative Legal (www.transformativelegal.com) for the outstanding job they did in drafting and prosecuting this application. This achievement is a major milestone for MBFT.”

About MBF Therapeutics

MBF Therapeutics is an immunotherapeutics company developing and commercializing proprietary T cell technology for infectious diseases in animals with significant translational applications in human health. The T-Max™ platform elicits mucosal immunity by activating innate and cell-mediated immunity through the administration of antigens that protect against infection and prevent person-to-person disease transmission. CaptaVax™ nanoparticles, a proprietary nonviral delivery system licensed from the Southwest Research Institute, provides MBF Therapeutics with a powerful platform technology from which multiple innovative products are being developed for veterinary medicine and human health. For more information, visit www.mbftherapeutics.com.

About Transformative Legal

Transformative Legal is an upcoming legal services company dedicated to offering alternatives to traditional law firm service models for innovative people and organizations. Transformative focuses on areas of the law that are most relevant to innovators, including patent, trademark, and other intellectual property-related services; transactional matters including licensing, small and mid-scale M&A, and other technology-related agreements; and select regulatory, corporate, and compliance matters. Transformative is innovative legal to innovative people. For more information, visit www.transformativelegal.com.